Ines Macias‐Perez

733 total citations
17 papers, 600 citations indexed

About

Ines Macias‐Perez is a scholar working on Molecular Biology, Pharmacology and Genetics. According to data from OpenAlex, Ines Macias‐Perez has authored 17 papers receiving a total of 600 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Pharmacology and 4 papers in Genetics. Recurrent topics in Ines Macias‐Perez's work include Chronic Lymphocytic Leukemia Research (4 papers), Inflammatory mediators and NSAID effects (4 papers) and Eicosanoids and Hypertension Pharmacology (3 papers). Ines Macias‐Perez is often cited by papers focused on Chronic Lymphocytic Leukemia Research (4 papers), Inflammatory mediators and NSAID effects (4 papers) and Eicosanoids and Hypertension Pharmacology (3 papers). Ines Macias‐Perez collaborates with scholars based in United States, United Kingdom and Denmark. Ines Macias‐Perez's co-authors include Ambra Pozzi, Roy Zent, Jorge H. Capdevila, Shouzuo Wei, Ian W. Flinn, Richard Breyer, Xuexian Yan, Su Yan, Matthew D. Breyer and John R. Falck and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Circulation Research.

In The Last Decade

Ines Macias‐Perez

16 papers receiving 597 citations

Peers

Countries citing papers authored by Ines Macias‐Perez

Since Specialization

Citations

This map shows the geographic impact of Ines Macias‐Perez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ines Macias‐Perez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ines Macias‐Perez more than expected).

Fields of papers citing papers by Ines Macias‐Perez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ines Macias‐Perez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ines Macias‐Perez. The network helps show where Ines Macias‐Perez may publish in the future.

Co-authorship network of co-authors of Ines Macias‐Perez

This figure shows the co-authorship network connecting the top 25 collaborators of Ines Macias‐Perez. A scholar is included among the top collaborators of Ines Macias‐Perez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ines Macias‐Perez. Ines Macias‐Perez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Real-world evaluation of select adverse drug reactions and healthcare utilization associated with parenteral Ibuprofen and ketorolac in adult and pediatric patients 2025 ·Frontiers in Pain Research ·(unknown), (unknown), (unknown), Ines Macias‐Perez, (unknown), (unknown), Theresa Human	0
2	Intravenous Ibuprofen Reduces Opioid Consumption During the Initial 48 Hours After Injury in Orthopedic Trauma Patients 2020 ·Journal of Orthopaedic Trauma ·(unknown), Alexander A. Fokin, (unknown), Amy Flynt, Ines Macias‐Perez, Leo Pavliv, (unknown), Ivan Puente	12
3	Antagonism of the Thromboxane‐Prostanoid Receptor as a Potential Therapy for Cardiomyopathy of Muscular Dystrophy 2019 ·Journal of the American Heart Association ·James West, Cristi L. Galindo, Kyung-Soo Kim, (unknown), James B. Atkinson, Ines Macias‐Perez, Leo Pavliv, Björn C. Knollmann, Jonathan H. Soslow, Larry W. Markham, Erica J. Carrier	13
4	Abstract 261: Activation of the Thromboxane/Prostanoid Receptor Contributes to Elevated End-Diastolic Calcium in Cardiomyocytes and Cardiac Fibrosis Following Right Ventricular Pressure Overload 2018 ·Circulation Research ·Erica J. Carrier, Kyung-Soo Kim, (unknown), Ines Macias‐Perez, W. David Merryman, Björn C. Knollmann, James West	2
5	Fewer adverse effects associated with a modified two-bag intravenous acetylcysteine protocol compared to traditional three-bag regimen in paracetamol overdose 2018 ·Clinical Toxicology ·Lars E. Schmidt, (unknown), Tonny Studsgaard Petersen, Ines Macias‐Perez, Leo Pavliv, (unknown), Richard C. Dart, Kim Dalhoff	27
6	B-Cell Receptor Pathobiology and Targeting in NHL 2012 ·Current Oncology Reports ·Ines Macias‐Perez, Ian W. Flinn	11
7	GS-1101: A Delta-Specific PI3K Inhibitor in Chronic Lymphocytic Leukemia 2012 ·Current Hematologic Malignancy Reports ·Ines Macias‐Perez, Ian W. Flinn	37
8	A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, 2011 ·Blood ·Ian W. Flinn, William N. Harwin, Ines Macias‐Perez, Patrick S. Tucker, David Waterhouse, Steven W. Papish, Jeffrey A. Jones, John D. Hainsworth, John C. Byrd	18
9	5.30 Preliminary Results from a Phase I/II Study of Fludarabine (F), Rituximab (R), and Lenalidomide (L) in Untreated Patients with Chronic Lymphocytic Leukemia (CLL) 2011 ·Clinical Lymphoma Myeloma & Leukemia ·Ian W. Flinn, Ines Macias‐Perez, Patrick S. Tucker, Richard Cooper, (unknown), Dana S. Thompson, Jesús G. Berdeja, John D. Hainsworth	9
10	A Phase II Trial of Combined Bendamustine, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma (MM) Patients Who Are Not Candidates for High-Dose Chemotherapy: Results of a Planned Interim Safety Analysis 2011 ·Blood ·Jesús G. Berdeja, Daniel R. Couriel, Patrick Murphy, Ralph V. Boccia, Victor Priego, John D. Hainsworth, Ines Macias‐Perez, Ian W. Flinn	2
11	Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site 2010 ·Cancer ·John D. Hainsworth, David R. Spigel, Howard A. Burris, Dianna Shipley, C. Farley, Ines Macias‐Perez, John H. Barton, F. Anthony Greco	14
12	Preliminary Results of a Phase II Trial of Panobinostat (LBH589) In Refractory Myelodysplastic Syndromes (MDS) Patients 2010 ·Blood ·Ian W. Flinn, (unknown), Eric Raefsky, Ralph V. Boccia, Ines Macias‐Perez, Howard A. Burris, John D. Hainsworth	7
13	Loss of Integrin α1β1 Ameliorates Kras-Induced Lung Cancer 2008 ·Cancer Research ·Ines Macias‐Perez, Corina M. Borza, Xiwu Chen, Xuexian Yan, (unknown), Glenda Mernaugh, Lynn M. Matrisian, Roy Zent, Ambra Pozzi	37
14	Mouse EP3 α, β, and γ Receptor Variants Reduce Tumor Cell Proliferation and Tumorigenesis in Vivo 2008 ·Journal of Biological Chemistry ·Ines Macias‐Perez, Roy Zent, Monica Carmosino, Matthew D. Breyer, Richard Breyer, Ambra Pozzi	24
15	Prostaglandin E2-EP4 Receptor Promotes Endothelial Cell Migration via ERK Activation and Angiogenesis in Vivo 2007 ·Journal of Biological Chemistry ·Reena Rao, Reyadh Redha, Ines Macias‐Perez, Su Yan, Chuan‐Ming Hao, Roy Zent, Matthew D. Breyer, Ambra Pozzi	114
16	Characterization of 5,6- and 8,9-Epoxyeicosatrienoic Acids (5,6- and 8,9-EET) as Potent in Vivo Angiogenic Lipids 2005 ·Journal of Biological Chemistry ·Ambra Pozzi, Ines Macias‐Perez, (unknown), Shouzuo Wei, Su Yan, Roy Zent, John R. Falck, Jorge H. Capdevila	147
17	Colon Carcinoma Cell Growth Is Associated with Prostaglandin E2/EP4 Receptor-evoked ERK Activation 2004 ·Journal of Biological Chemistry ·Ambra Pozzi, Xuexian Yan, Ines Macias‐Perez, Shouzuo Wei, Aaron N. Hata, Richard Breyer, Jason D. Morrow, Jorge H. Capdevila	126

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact